Investor Panacea Innovation Ltd
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Panacea Innovation Ltd . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2025-08-19 13D/A 1,712,900
2025-07-21 13D/A CNTB / Connect Biopharma Holdings Limited - Depositary Receipt (Common Stock) 13,410,000 13,950,000
2025-05-21 13D 1,638,565
2025-02-14 13G/A AMLX / Amylyx Pharmaceuticals, Inc. 4,200,000 2,200,000
2025-02-14 13G/A MRNS / Marinus Pharmaceuticals, Inc. 5,500,000 0
2025-02-14 13G/A ADAG / Adagene Inc. - Depositary Receipt (Common Stock) 3,037,500
2025-02-06 13G ATRA / Atara Biotherapeutics, Inc. 550,000
2024-11-01 13G MRNS / Marinus Pharmaceuticals, Inc. 5,500,000
2024-07-01 13D/A CNTB / Connect Biopharma Holdings Limited - Depositary Receipt (Common Stock) 12,000,000 13,410,000
2024-03-11 13G AMLX / Amylyx Pharmaceuticals, Inc. 4,200,000
2024-02-27 13D/A CNTB / Connect Biopharma Holdings Limited - Depositary Receipt (Common Stock) 8,900,000 12,000,000
2024-02-13 13D CNTB / Connect Biopharma Holdings Limited - Depositary Receipt (Common Stock) 8,900,000